BACKGROUND: Among glucocorticoids, dexamethasone is most widely used for treatment of cerebral edema because of its long biological half-life and its low mineralocorticoid activity (sodium retaining). OBJECTIVE: A systematic review of the literature on the effects of dexamethasone on the brain from in vivo studies in humans. METHODS: A MEDLINE database search (via the PubMed interface) and an EMBASE database search (via the Dialog interface) of the past 35 years was performed. Every article relating to human use reported in English was included. In addition, references of all eligible articles were searched to identify other possible sources. RESULTS: Twenty-four articles matched the eligibility criteria. There were disparate methodologies and conflicting results, although they tended to indicate a decrease in blood-tumor barrier permeability, decreased tumoral perfusion, decreased tumoral diffusivity, and the possibility of decreased perfusion in contralateral normal-appearing brain tissue. CONCLUSION: Treatment with dexamethasone may alter imaging parameters from cerebral perfusion studies used in the management of brain tumors. In adequately powered studies, it may be possible to assess the longer term effects of dexamethasone on normal brain tissue to help optimize use with longer term survivors that are emerging as improvements in glioma treatment are made.
BACKGROUND: Among glucocorticoids, dexamethasone is most widely used for treatment of cerebral edema because of its long biological half-life and its low mineralocorticoid activity (sodium retaining). OBJECTIVE: A systematic review of the literature on the effects of dexamethasone on the brain from in vivo studies in humans. METHODS: A MEDLINE database search (via the PubMed interface) and an EMBASE database search (via the Dialog interface) of the past 35 years was performed. Every article relating to human use reported in English was included. In addition, references of all eligible articles were searched to identify other possible sources. RESULTS: Twenty-four articles matched the eligibility criteria. There were disparate methodologies and conflicting results, although they tended to indicate a decrease in blood-tumor barrier permeability, decreased tumoral perfusion, decreased tumoral diffusivity, and the possibility of decreased perfusion in contralateral normal-appearing brain tissue. CONCLUSION: Treatment with dexamethasone may alter imaging parameters from cerebral perfusion studies used in the management of brain tumors. In adequately powered studies, it may be possible to assess the longer term effects of dexamethasone on normal brain tissue to help optimize use with longer term survivors that are emerging as improvements in glioma treatment are made.
Authors: Csaba Juhász; Diane C Chugani; Geoffrey R Barger; William J Kupsky; Pulak K Chakraborty; Otto Muzik; Sandeep Mittal Journal: Clin Nucl Med Date: 2012-09 Impact factor: 7.794
Authors: Carina Stegmayr; Ulrike Bandelow; Dennis Oliveira; Philipp Lohmann; Antje Willuweit; Christian Filss; Norbert Galldiks; Joachim H R Lübke; N Jon Shah; Johannes Ermert; Karl-Josef Langen Journal: Eur J Nucl Med Mol Imaging Date: 2016-09-09 Impact factor: 9.236
Authors: Kenneth L Pitter; Ilaria Tamagno; Kristina Alikhanyan; Amira Hosni-Ahmed; Siobhan S Pattwell; Shannon Donnola; Charles Dai; Tatsuya Ozawa; Maria Chang; Timothy A Chan; Kathryn Beal; Andrew J Bishop; Christopher A Barker; Terreia S Jones; Bettina Hentschel; Thierry Gorlia; Uwe Schlegel; Roger Stupp; Michael Weller; Eric C Holland; Dolores Hambardzumyan Journal: Brain Date: 2016-03-28 Impact factor: 13.501
Authors: Carina Stegmayr; Michael Schöneck; Dennis Oliveira; Antje Willuweit; Christian Filss; Norbert Galldiks; N Jon Shah; Heinz H Coenen; Karl-Josef Langen Journal: Eur J Nucl Med Mol Imaging Date: 2015-12-08 Impact factor: 9.236
Authors: Stuart I Jenkins; Mark R Pickard; Melinda Khong; Heather L Smith; Carl L A Mann; Richard D Emes; Divya M Chari Journal: ACS Chem Neurosci Date: 2013-11-07 Impact factor: 4.418